{"id":1167,"date":"2016-12-16T16:28:55","date_gmt":"2016-12-16T16:28:55","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=1167"},"modified":"2016-12-16T16:28:55","modified_gmt":"2016-12-16T16:28:55","slug":"enyo-pharma-sa-annonce-linitiation-de-la-phase-1-des-etudes-cliniques-avec-eyp001-son-premier-compose-pour-le-traitement-de-linfection-chronique-par-le-virus-de-lhepatite","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-sa-annonce-linitiation-de-la-phase-1-des-etudes-cliniques-avec-eyp001-son-premier-compose-pour-le-traitement-de-linfection-chronique-par-le-virus-de-lhepatite\/","title":{"rendered":"ENYO Pharma SA annonce l\u2019initiation de la Phase 1 des \u00e9tudes cliniques avec EYP001, son premier compos\u00e9 pour le traitement de l\u2019infection chronique par le Virus de  l\u2019H\u00e9patite B"},"content":{"rendered":"<p>Lyon, 16 D\u00e9cembre 2016 &#8211; ENYO Pharma SA, une entreprise biopharmaceutique priv\u00e9e actuellement focalis\u00e9e sur le d\u00e9veloppement de traitements antiviraux, a annonc\u00e9 aujourd\u2019hui que l\u2019\u00e9tude clinique de Phase 1 \u00e0 dose unique ou multiple et mesurant l\u2019innocuit\u00e9 de EYP001 chez le sujet sain a \u00e9t\u00e9 initi\u00e9e, et que l\u2019essai d\u2019augmentation de dose unique est d\u00e9j\u00e0 compl\u00e9t\u00e9. Les r\u00e9sultats ont montr\u00e9 que EYP001 est bien tol\u00e9r\u00e9 \u00e0 toutes les doses ayant \u00e9t\u00e9 \u00e9tudi\u00e9es chez 46 sujets sains. La s\u00e9curit\u00e9 du m\u00e9dicament et l\u2019analyse pharmacocin\u00e9tique (PK) de ces premi\u00e8res donn\u00e9es de Phase 1 seront compl\u00e8tes d\u2019ici au 2\u00e8me trimestre 2017.<\/p>\n <a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2016\/12\/PR-FR-ENYO-December-16-2016-Final.pdf\" target=\"_blank\" rel=\"\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">T\u00e9l\u00e9charger le communiqu\u00e9 complet (PDF)<\/span><\/a> \n","protected":false},"excerpt":{"rendered":"<p>Lyon, 16 D\u00e9cembre 2016 &#8211; ENYO Pharma SA, une entreprise biopharmaceutique priv\u00e9e actuellement focalis\u00e9e sur le d\u00e9veloppement de traitements antiviraux, a annonc\u00e9 aujourd\u2019hui que l\u2019\u00e9tude clinique de Phase 1 \u00e0 dose unique ou multiple et mesurant l\u2019innocuit\u00e9 de EYP001 chez le sujet sain a \u00e9t\u00e9 initi\u00e9e, et que l\u2019essai d\u2019augmentation de dose unique est d\u00e9j\u00e0 compl\u00e9t\u00e9. Les r\u00e9sultats ont montr\u00e9 que EYP001 est bien tol\u00e9r\u00e9 \u00e0 toutes les doses ayant \u00e9t\u00e9 \u00e9tudi\u00e9es chez 46 sujets sains.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-sa-annonce-linitiation-de-la-phase-1-des-etudes-cliniques-avec-eyp001-son-premier-compose-pour-le-traitement-de-linfection-chronique-par-le-virus-de-lhepatite\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-1167","post","type-post","status-publish","format-standard","hentry","category-press-releases-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/press-releases-fr\/\" rel=\"category tag\">Press releases<\/a>","rttpg_excerpt":"Lyon, 16 D\u00e9cembre 2016 &#8211; ENYO Pharma SA, une entreprise biopharmaceutique priv\u00e9e actuellement focalis\u00e9e sur le d\u00e9veloppement de traitements antiviraux, a annonc\u00e9 aujourd\u2019hui que l\u2019\u00e9tude clinique de Phase 1 \u00e0 dose unique ou multiple et mesurant l\u2019innocuit\u00e9 de EYP001 chez le sujet sain a \u00e9t\u00e9 initi\u00e9e, et que l\u2019essai d\u2019augmentation de dose unique est d\u00e9j\u00e0&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=1167"}],"version-history":[{"count":1,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1167\/revisions"}],"predecessor-version":[{"id":1168,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1167\/revisions\/1168"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=1167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=1167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=1167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}